Edition:
United States

Zogenix Inc (ZGNX.OQ)

ZGNX.OQ on NASDAQ Stock Exchange Global Market

13.75USD
3:04pm EDT
Change (% chg)

$0.15 (+1.10%)
Prev Close
$13.60
Open
$13.60
Day's High
$13.98
Day's Low
$13.50
Volume
19,070
Avg. Vol
45,367
52-wk High
$15.30
52-wk Low
$7.50

Latest Key Developments (Source: Significant Developments)

Zogenix says FDA granted ZX008 orphan drug designation for LGS
Thursday, 22 Jun 2017 07:42am EDT 

June 22 (Reuters) - Zogenix Inc ::Zogenix Inc - on June 22 U.S. FDA granted its investigational drug, ZX008 orphan drug designation for treatment of Lennox Gastaut Syndrome.Zogenix Inc - intends to initiate Phase 3 clinical trial in LGS in second half of 2017 - SEC filing.Zogenix Inc - company expects that first patients will enroll in planned LGS study in Q4 of 2017.Zogenix Inc - top-line data for co's Phase 3 pivotal study in Dravet Syndrome are expected in Q3 of 2017.  Full Article

Zogenix Q1 loss per share $0.86
Thursday, 4 May 2017 04:01pm EDT 

May 4 (Reuters) - Zogenix Inc ::Zogenix provides corporate update and reports first quarter 2017 financial results.Q1 loss per share $0.86.Q1 revenue $2.7 million.Q1 earnings per share view $-0.88 -- Thomson Reuters I/B/E/S.Q1 revenue view $4.2 million -- Thomson Reuters I/B/E/S.  Full Article

Zogenix completes enrollment in first ZX008 Phase 3 clinical trial in Dravet syndrome
Thursday, 27 Apr 2017 08:01am EDT 

April 27 (Reuters) - Zogenix Inc :Zogenix completes enrollment in first zx008 phase 3 clinical trial in dravet syndrome.Zogenix inc- availability of top-line data from the study, expected in q3 of this year zx008 phase 3 for.  Full Article

Zogenix Q4 loss per share $0.95
Thursday, 9 Mar 2017 04:01pm EST 

Zogenix Inc : Zogenix provides corporate update and reports fourth quarter and full-year 2016 financial results . Q4 loss per share $0.95 . Q4 revenue $11 million . Q4 earnings per share view $-0.84 -- Thomson Reuters I/B/E/S .Q4 revenue view $5.2 million -- Thomson Reuters I/B/E/S.  Full Article

Zogenix receives orphan drug designation in the EU for zx008 in lennox gastaut syndrome
Wednesday, 1 Mar 2017 08:00am EST 

Zogenix Inc : Zogenix Inc- receives orphan drug designation in european union for zx008 in lennox gastaut syndrome .Zogenix Inc- intend to move forward with a phase 3 clinical study for zx008 in lgs in second half of 2017.  Full Article

Perceptive Advisors LLC reports 5.46 pct passive stake in Zogenix
Wednesday, 22 Feb 2017 09:46am EST 

Zogenix Inc :Perceptive Advisors LLC reports 5.46 percent passive stake in Zogenix Inc as of Feb 15 - sec filing.  Full Article

Zogenix amends manufacturing services agreement
Friday, 26 Aug 2016 04:12pm EDT 

Zogenix Inc [ZGNX.O] : Zogenix Inc Co, Patheon UK limited entered into amendment to the manufacturing services agreement, dated February 28, 2013 .The expiration of the term of the services agreement has been retroactively extended from July 31, 2016 to October 31, 2016 - SEC filing.  Full Article

Zogenix Q2 loss per share $0.76
Tuesday, 9 Aug 2016 04:01pm EDT 

Zogenix Inc : Zogenix provides corporate update and reports second quarter 2016 financial results . Q2 earnings per share view $-0.81 -- Thomson Reuters I/B/E/S . Q2 revenue view $5.4 million -- Thomson Reuters I/B/E/S . Q2 loss per share $0.76 . Q2 revenue $2.1 million .Zogenix inc says zogenix is reiterating its previously provided financial guidance for full year 2016.  Full Article

Zogenix to refinance debt, increasing expected 2017 cash balance
Tuesday, 21 Jun 2016 08:00am EDT 

Zogenix Inc : Zogenix announces agreement to refinance debt, further increasing company's expected 2017 cash balance . Continues to expect its cash runway to extend through end of 2017. . Entered into an amendment to its existing term loan facility with oxford finance llc and silicon valley bank . New loan proceeds will increase total amount of term loan principal outstanding to $20 million . Entered into an amendment to provide for new term loans and partially refinance its existing long-term debt under facility . Agreement is expected to result in an increase of approximately $10 million to zogenix's expected cash balance at end of 2017 . Zogenix continues to expect its cash runway to extend through end of 2017 .Term loan facility provides for interest-only payments through feb 2018 followed by consecutive monthly payments of principal and interest until maturity on july 1, 2020.  Full Article

Zogenix Q1 loss per share $0.42
Tuesday, 10 May 2016 04:01pm EDT 

Zogenix Inc : Zogenix Inc says is reiterating its previously provided financial guidance for full year 2016 . Zogenix provides corporate update and reports first quarter 2016 financial results . Q1 loss per share $0.42 . Q1 earnings per share view $-0.62 -- Thomson Reuters I/B/E/S . Q1 revenue $9.2 million .Q1 revenue view $4.9 million -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Zogenix Q1 loss per share $0.86

* Zogenix provides corporate update and reports first quarter 2017 financial results